United Therapeutics Corporation (NASDAQ:UTHR) Position Increased by LPL Financial LLC

LPL Financial LLC grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 77.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,246 shares of the biotechnology company's stock after acquiring an additional 11,007 shares during the period. LPL Financial LLC owned about 0.06% of United Therapeutics worth $7,783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of UTHR. Anchor Investment Management LLC boosted its stake in shares of United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 30 shares in the last quarter. Hohimer Wealth Management LLC grew its position in United Therapeutics by 0.3% during the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock valued at $3,900,000 after buying an additional 37 shares during the period. Applied Finance Capital Management LLC grew its position in United Therapeutics by 3.7% during the first quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock valued at $349,000 after buying an additional 40 shares during the period. Dunhill Financial LLC grew its position in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 50 shares during the period. Finally, Two Sigma Investments LP boosted its position in United Therapeutics by 3.0% during the fourth quarter. Two Sigma Investments LP now owns 1,773 shares of the biotechnology company's stock worth $626,000 after acquiring an additional 52 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $10,297,208.76. The trade was a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nilda Mesa sold 645 shares of the business's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director directly owned 4,883 shares in the company, valued at approximately $1,416,021.17. The trade was a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 81,681 shares of company stock valued at $24,618,359. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Up 2.8%

Shares of NASDAQ UTHR traded up $8.33 during midday trading on Wednesday, reaching $309.72. 579,471 shares of the stock were exchanged, compared to its average volume of 520,965. The company has a market capitalization of $13.97 billion, a P/E ratio of 12.09, a P/E/G ratio of 4.55 and a beta of 0.57. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82. The stock has a 50 day moving average price of $295.69 and a 200-day moving average price of $310.03.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company's quarterly revenue was up 11.7% on a year-over-year basis. During the same period last year, the firm earned $5.85 earnings per share. On average, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on UTHR. Cantor Fitzgerald began coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target on the stock. Bank of America decreased their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research note on Wednesday, June 11th. UBS Group increased their price target on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday. Wells Fargo & Company cut their price target on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Finally, HC Wainwright set a $400.00 price target on shares of United Therapeutics and gave the company a "buy" rating in a report on Thursday, July 31st. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $382.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.